Magnetic gel takes aim at oral cancer risk
NCT ID NCT06271564
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a gel containing magnetite zinc oxide nanoparticles on 24 people with oral precancerous lesions. The gel was applied three times daily for six weeks. Researchers measured changes in lesion size and tissue health. This is an early trial to see if the gel is safe and might work.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Magnetite zinc oxide composite nanoparticle gel
- What this could lead to
- If it works, this could offer a simple gel treatment for oral precancerous lesions, potentially avoiding surgery.
- What could go wrong
- This is a very early, small trial with only 24 people. The gel has only been tested in lab dishes before, so it may not work in humans or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
24 people
The number who actually took part.
- Started
-
Feb 2024
- Finished
-
Apr 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
25 to 60 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Both genders ranged from 25 to 60 years. * Clinically confirmed OPMLs: the clinical picture of oral erythroplakia includes well-demarcated red discs with a smooth or granular surface, leukoplakia is classified into four clinical types: type I, a flat white patch or plaque without red components; type II, a flat white patch or plaque with red components; type III, a slightly raised or elevated white plaque; and type IV, a markedly raised or elevated white plaque. * Histopathological confirmed OPMLs with low or moderate dysplasia Exclusion Criteria: * Presence of systemic conditions as serious active or recurrent infections, malignancy, diabetes mellitus, hypertension, or significant heart, liver, or renal diseases. Assessed using a medical questionnaire guided by Cornell Medical Index * Smoking 6 weeks before the clinical trial * Known hypersensitivity or severe adverse effects to the treatment drugs or to any ingredient of their preparation as mentioned in history. * Pregnancy or breastfeeding. * Histological diagnosis of severe, or invasive oral squamous cell carcinoma. * Vulnerable groups (Handicapped, orphans or prisoners). * Any lesion less than 1 cm in diameter.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Oral potentially malignant lesions are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Faculty of Dentistry Ain shams University
Cairo, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.